123 related articles for article (PubMed ID: 27284441)
1. Lateral differences in Ki-67 in breast cancer.
Dmitrenko AP
Mol Clin Oncol; 2016 Jun; 4(6):1041-1044. PubMed ID: 27284441
[TBL] [Abstract][Full Text] [Related]
2. Lower incidence but more aggressive behavior of right sided breast cancer in Pakistani women: does right deserve more respect?
Fatima N; Zaman MU; Maqbool A; Khan SH; Riaz N
Asian Pac J Cancer Prev; 2013; 14(1):43-5. PubMed ID: 23534768
[TBL] [Abstract][Full Text] [Related]
3. Effect of Hydrochloric Acid Decalcification on Expression Pattern of Prognostic Markers in Invasive Breast Carcinomas.
Maclary SC; Mohanty SK; Bose S; Chung F; Balzer BL
Appl Immunohistochem Mol Morphol; 2017 Feb; 25(2):144-149. PubMed ID: 27028239
[TBL] [Abstract][Full Text] [Related]
4. Clinical and histopathological factors associated with Ki-67 expression in breast cancer patients.
Alco G; Bozdogan A; Selamoglu D; Pilanci KN; Tuzlali S; Ordu C; Igdem S; Okkan S; Dincer M; Demir G; Ozmen V
Oncol Lett; 2015 Mar; 9(3):1046-1054. PubMed ID: 25663855
[TBL] [Abstract][Full Text] [Related]
5. Laterality of breast cancer at Dr George Mukhari Academic Hospital.
Mokone-Fatunla DH; Koto MZ; Becker JHR; Bondo M; Mundawarara S
S Afr J Surg; 2019 Sep; 57(3):56. PubMed ID: 31392868
[TBL] [Abstract][Full Text] [Related]
6. Divergent Impact of Breast Cancer Laterality on Clinicopathological, Angiogenic, and Hemostatic Profiles: A Potential Role of Tumor Localization in Future Outcomes.
Barbara RC; Piotr R; Kornel B; Elżbieta Z; Danuta R; Eduardo N
J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32498398
[TBL] [Abstract][Full Text] [Related]
7. Association of mammographic density with the proliferation marker Ki-67 in a cohort of patients with invasive breast cancer.
Heusinger K; Jud SM; Häberle L; Hack CC; Fasching PA; Meier-Meitinger M; Lux MP; Hagenbeck C; Loehberg CR; Wittenberg T; Rauh C; Wagner F; Uder M; Hartmann A; Schulz-Wendtland R; Beckmann MW; Wachter DL
Breast Cancer Res Treat; 2012 Oct; 135(3):885-92. PubMed ID: 22936391
[TBL] [Abstract][Full Text] [Related]
8. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.
Konecny G; Pauletti G; Pegram M; Untch M; Dandekar S; Aguilar Z; Wilson C; Rong HM; Bauerfeind I; Felber M; Wang HJ; Beryt M; Seshadri R; Hepp H; Slamon DJ
J Natl Cancer Inst; 2003 Jan; 95(2):142-53. PubMed ID: 12529347
[TBL] [Abstract][Full Text] [Related]
9. Epithelial ovarian tumors: Clinicopathological correlation and immunohistochemical study.
Naik PS; Deshmukh S; Khandeparkar SG; Joshi A; Babanagare S; Potdar J; Risbud NS
J Midlife Health; 2015; 6(4):178-83. PubMed ID: 26903759
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients.
Petrelli F; Viale G; Cabiddu M; Barni S
Breast Cancer Res Treat; 2015 Oct; 153(3):477-91. PubMed ID: 26341751
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan.
Almasri NM; Al Hamad M
Breast Cancer Res; 2005; 7(5):R598-604. PubMed ID: 16168103
[TBL] [Abstract][Full Text] [Related]
12. [Expression discordances and clinical values of ER, PR, HER-2 and Ki-67 in primary and metastatic breast cancer].
Yuan Y; Hu SN; Gao J; Yu Q; Hu YQ; Xu XY; Gao ZG; Zhang J; Zhang Z; Teng Y; Zhang LL
Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):681-685. PubMed ID: 31550858
[No Abstract] [Full Text] [Related]
13. Multicentric mammary carcinoma: evidence of monoclonal proliferation.
Middleton LP; Vlastos G; Mirza NQ; Eva S; Sahin AA
Cancer; 2002 Apr; 94(7):1910-6. PubMed ID: 11932891
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of changes in biologic markers ER, PR, HER 2 and Ki-67 index in breast cancer with administration of neoadjuvant dose dense doxorubicin, cyclophosphamide followed by paclitaxel chemotherapy.
Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y
J BUON; 2013; 18(2):366-71. PubMed ID: 23818347
[TBL] [Abstract][Full Text] [Related]
15. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel.
Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y
J BUON; 2013; 18(1):57-63. PubMed ID: 23613389
[TBL] [Abstract][Full Text] [Related]
17. [Breast cancer with triple-negative phenotype in the Russian patient population. Clinical and morphologic features].
Zhukova LG
Vopr Onkol; 2015; 61(2):189-94. PubMed ID: 26087596
[TBL] [Abstract][Full Text] [Related]
18. Prognostic variables in invasive breast cancer: contribution of comedo versus noncomedo in situ component.
Brower ST; Ahmed S; Tartter PI; Bleiweiss I; Amberson JB
Ann Surg Oncol; 1995 Sep; 2(5):440-4. PubMed ID: 7496840
[TBL] [Abstract][Full Text] [Related]
19. Relationship of cell proliferation (Ki-67) to 99mTc-(V)DMSA uptake in breast cancer.
Papantoniou VJ; Souvatzoglou MA; Valotassiou VJ; Louvrou AN; Ambela C; Koutsikos J; Lazaris D; Christodoulidou JK; Sotiropoulou MG; Melissinou MJ; Perperoglou A; Tsiouris S; Zerva CJ
Breast Cancer Res; 2004; 6(2):R56-62. PubMed ID: 14979918
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
